Objective: To investigate the value of dynamic monitoring of procalcitonin(PCT), C-reaction protein (CRP) and WBC in acute brucellosis patients. Methods: A total of 151 patients with acute brucellosis, 120 patients with chronic brucellosis and 72 healthy controls were recruited in this study. The levels of PCT, CRP and WBC were detected and the results before and after therapy were compared. Results: Of the 151 acute brucellosis patients the level of PCT was(3.29±0.49) ng/mL with positive rate of 65.56%, the level of CRP was(24.84±2.95) mg/L with positive rate of 56.29% , and the WBC count was (7.53±3.42)×109/L with positive rate of 7.28%. The levels of PCT, CRP and WBC in 120 cases of chronic brucellosis patients were (0.27±0.03) ng/mL, (3.32±0.35) mg/L and (6.27±2.56)×109/L, respectively, and the positive rates were 7.50%, 8.33% and 6.67% , respectively. The levels of PCT, CRP and WBC in 72 healthy controls were(0.21±0.01) ng/mL, (2.93±0.35) mg/L and (5.91±2.31)×109/L, respectively. The differences in levels of PCT, CRP were statistically significant between acute brucellosis group, chronic brucellosis group and healthy control group(P<0.01), but there was no significant difference in WBC count between the three groups. The sensitivity, specificity, Youden index, positive predictive value and negative predictive value of PCT for diagnosing acute brucellosiswere higher than those of CRP, and the combined detection of PCT and CRP showed the highest sensitivity and negative predictive value. In acute brucellosis group the levels of PCT and CRP after treatment were lower than those before treatment, and the differences were statistically significant(P<0.05). Conclusions: Combined detection of levels of procalcitonin and C-reactive protein could increase the sensitivity for diagnosing acute brucellosis, and monitoring of levels of procalcitonin and C-reactive protein in treatment of acute brucellosis has value in predicting the outcome.
HE Jingjing, ZHANG Yan, ZHOU Yuzhen, LIU Jingyao, ZHAO Dongmei, ZHENG Zunrong
. Dynamic monitoring of levels of procalcitonin and C-reactive protein in acute brucellosis[J]. Journal of Diagnostics Concepts & Practice, 2017
, 16(06)
: 617
-621
.
DOI: 10.16150/j.1671-2870.2017.06.011
[1] 朱素娟, 徐卫民, 金行一, 等. 浙江省布鲁杆菌病流行病学特征回顾性分析[J]. 中国地方病学杂志,2014,33(4):425-428.
[2] Christ-Crain M, Morgenthaler NG, Fenske W.Copeptin as a biomarker and a diagnostic tool in the evaluation of patients with polyuria-polydipsia and hyponatremia[J]. Best Pract Res Clin Endocrinol Metab,2016,30(2):235-247.
[3] Marková M, Brodská H, Malíčková K, et al.Substantially elevated C-reactive protein (CRP), together with low leve-ls of procalcitonin(PCT), contributes to diagnosis of fungal infection in immunocompromised patients[J]. Support Care Cancer,2013,21(10):2733-2742.
[4] 刘名鑫, 刘莉. CRP和PCT检测对重症急性肾盂肾炎患者临床应用价值[J]. 检验医学与临床,2016,13(7):961-962.
[5] 马清峰, 熊亮. 细菌性肺炎患者血清降钙素原和超敏C反应蛋白水平分析[J]. 微循环学杂志,2015,25(2):41-43.
[6] Jung SJ, Lee JH.Prediction of Cortical defect using C-reactive protein and urine sodium to potassium ratio in infants with febrile urinary tract infection[J]. Yonsei Med J,2016,57(1):103-110.
[7] Yao A, Liu J, Chang J, et al.Clinical practice of procalcitonin and hypersensitive c-reactive protein test in neonatal infection[J]. Pak J Pharm Sci,2016,29(2 Suppl):753-756.
[8] 黄佳玲, 田海荣, 刘沫然, 等. T淋巴细胞亚群与淋巴细胞及C-反应蛋白在急慢性布鲁杆菌病诊断中的临床意义[J]. 中国地方病防治杂志,2016,31(8):898.
[9] Demirdag K, Ozden M, Kalkan A, et al.Serum cytokine levels in patients with acute brucellosis and their relation to the traditional inflammatory markers[J]. FEMS Immunol Med Microbiol,2003,39(2):149-153.
[10] 董玉梅, 靳桂明, 吴颖涛, 等. 降钙素原对患者医院感染的诊断与预后的价值研究[J]. 中华医院感染学杂志,2016,26(3):682-684.
[11] 陆子贇, 彭怡倩, 应春妹. 降钙素原和C反应蛋白联合检测在新生儿感染性疾病诊断中的应用评估[J]. 诊断学理论与实践,2016,15(2):157-159.
[12] 彭宝玲, 朱翠平, 万根平. 降钙素原在儿童细菌感染性疾病中的应用[J]. 中华感染医学杂志,2012,22(14):3197-3200.
[13] 吴华家, 朱冬宁, 鲍俊, 等. 血清降钙素原在慢阻肺急性加重期患者抗感染治疗中的指导作用[J]. 安徽医学,2016,37(7):840-842.
[14] 王玉梅, 孙丽娟, 王善菊, 等. 血清PCT和CRP对社区获得性肺炎的诊断价值[J]. 放射免疫学杂志,2011,24(4):447-449.
[15] Vanagas G.Receiver operating characteristic curves and comparison of cardiac surgery risk stratification systems[J]. Interact Cardiovasc Thorac Surg,2004,3(2):319-322.
